Showing 2681-2690 of 7278 results for "".
- Study: Crotoxin Demonstrates Efficacy Against Melanoma with Reduced Toxicityhttps://practicaldermatology.com/news/crotoxin-demonstrates-efficacy-against-melanoma-reduced-toxicity/2467490/A new study in Frontiers in Pharmacology indicated that crotoxin (CTX), a component of snake venom, was associated with antiproliferative effects on melanoma cells. "Melanoma, a highly aggressive skin cancer originating in melanocytes, poses a significant threat due to its metast
- Powered By MRP Gets Series A Investmenthttps://practicaldermatology.com/news/powered-mrp-gets-series-investment/2467442/“Strong tailwinds behind the aesthetics market” was part of the impetus for two prominent growth equity firms to form a strategic partnership with aesthetics device company Powered By MRP, according to a press release. The Series A investment by Aries Capital Partners and Swell Collective
- AQUA Dermatology Partners With First Coast Mohshttps://practicaldermatology.com/news/aqua-dermatology-partners-first-coast-mohs/2467290/AQUA Dermatology, backed by private-equity firms Gryphon Investors and GTCR, announced it now has 110 locations in the southeastern United States and more than 250 practitioners as a result of a new partnership with Jacksonville, Florida-based First Coast Mohs. First Coast Mohs will conti
- England's NICE Recommends Lebrikizumab for Moderate-to-Severe ADhttps://practicaldermatology.com/news/englands-nice-recommends-lebrikizumab-moderate-severe-ad/2467289/England’s National Institute for Health and Care Excellence (NICE) has recommended lebrikizumab for use in treating moderate-to-severe atopic dermatitis, Almirall S.A. announced in a press release. Lebrikizumab, sold by Almirall under the brand name Ebglyss, is indicated for the treatment
- NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe AD in the NHS Englandhttps://practicaldermatology.com/news/nice-recommends-ebglyss-lebrikizumab-use-moderate-severe-ad-nhs-england/2467288/Almirall announced that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England. Lebrikizumab is indicated for the treatment of adult and adolescent patients (12 years and older
- FDA Approves sNDA for Roflumilast Cream, 0.15%, for Mild-to-Moderate ADhttps://practicaldermatology.com/news/fda-approves-snda-roflumilast-cream-015-mild-moderate-ad/2467287/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild-to-moderate atopic dermatitis (AD) in adult and pediatric patients 6 years of age and older, Arcutis Biotherapeutics, Inc. announc
- Study: 5-mm Margins Adequate for Small Melanoma in Situ Lesionshttps://practicaldermatology.com/news/study-5-mm-margins-adequate-small-mis-lesions/2467262/New research shed light on the recurrence rates of melanoma in situ (MIS) lesions removed with a 5-mm margin. "The incidence of MIS has increased significantly over the past decades, and traditional guidelines for treatment of MIS have been excision with a 5-mm clinical margin; however, c
- NEA Study Illuminates Gaps in Mental Health Help for Eczema Patientshttps://practicaldermatology.com/news/nea-study-illuminates-gaps-mental-health-help-eczema-patients/2467195/Forty-two percent of patients with atopic dermatitis (eczema) and caregivers of children/teens with the condition never spoke about mental health with primary eczema care providers, according to National Eczema Association (NEA
- Study: Oral Minoxidil Not Superior to Topical Minoxidilhttps://practicaldermatology.com/news/non-oral-and-topical-minoxidil/2467152/Daily oral minoxidil, 5 mg was not superior to topical minoxidil, 5%, in a population of male patients with alopecia according to a new study in JAMA Dermatology. "There has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment," the autho
- Study IDs New Potential Targets for Rare Complication of Melanomahttps://practicaldermatology.com/news/study-ids-new-potential-targets-rare-complication-melanoma/2467090/New research from the Moffitt Cancer Center may have uncovered new therapeutic targets for leptomeningeal metastasis (LMD) in melanoma, a severe complication affecting 5%-8% of melanoma patients.